SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is attracting significant investor attention following an oversubscribed private placement that provides the necessary capital to advance its FB102 drug candidate. Community sentiment is deeply polarized, with some traders highlighting the stock's low-float momentum and potential for short squeezes, while others remain skeptical due to the company's historical financial performance and the risk of further share dilution.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma (IMMX) is experiencing significant market interest driven by anticipation of upcoming Phase 2 trial data for its NXC-201 therapy, a potential breakthrough in AL amyloidosis treatment. The community is actively discussing the company's recent leadership transition, the strategic buildup of institutional ownership, and the potential for a regulatory-led rerating as the firm moves toward pivotal trial readouts.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is seeing heavy volatility as investors weigh the impact of rising jet fuel costs against a backdrop of intensifying geopolitical instability in the Middle East. While some market participants track the stock for short-term swing trading opportunities fueled by shifting peace deal narratives, others remain deeply concerned about the airline's unhedged fuel exposure and significant debt load.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as global investors react to a significant jump in liquefaction fees and intensifying geopolitical tensions in the Middle East that have disrupted critical energy shipping routes. Market participants are actively discussing the company's ability to capitalize on higher international gas spreads and expanding production capacity despite persistent volatility and ongoing debate regarding the impact of Middle Eastern conflicts on energy supply chains.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense market scrutiny and volatility as investors weigh the company's aggressive capital expenditures in AI and robotics against its disappointing earnings and margins. The community is sharply divided, with bulls pointing to the long-term potential of autonomous driving and Optimus robots as the next major growth wave, while bears remain focused on the company's high valuation and the ongoing uncertainty surrounding the timeline for these product launches.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta Air Lines is capturing investor attention as reports of a potential cease-fire in the Middle East drive optimism across the airline sector by alleviating concerns over record-high jet fuel costs. Community discussion remains heavily focused on the interplay between cooling energy prices, resilient travel demand, and Delta's recent quarterly performance, with traders actively debating how geopolitical developments will impact the company's margin recovery and capacity outlook.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is under significant market pressure as traders debate the company's valuation ahead of an imminent share lock-up expiration, leading to heavy speculation on whether recent technical launch successes can offset cooling sentiment. The community remains deeply divided, with bulls pointing to long-term infrastructure and Starlink potential while bears focus on cash burn and the risk of massive insider selling.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is facing significant downward pressure as investors weigh concerns over project execution timelines and share dilution against the stock's potential as a strategic rare earth supplier. While the community remains divided between those viewing the current price as a long-term accumulation opportunity and those frustrated by delayed milestones and perceived transparency issues, the stock remains a focal point for the broader geopolitical interest in securing non-Chinese mineral supply chains.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as investors digest a negative European regulatory opinion on Yartemlea, fueling community debates over long-term commercial strategy versus the importance of the US market. While some focus on the upcoming re-examination appeal, many are actively discussing potential buyouts, insider confidence through debt repurchases, and whether recent share price volatility offers a strategic entry point.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly anticipate upcoming Phase 3 IZAR-1 data, with community discussion centered on the potential for a significant re-rating of the stock following this clinical milestone. Sentiment is bolstered by ongoing speculation regarding potential M&A activity within the immunology sector, driving high engagement as shareholders monitor management's guidance on the trial's readout timeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally

Key Points4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average price of around $110.73 per share...

ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors

ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors PR Newswire BERKELEY, Calif., June 9, 2026 BERKELEY, Calif., June 9, 2026 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering a topical cell...

Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA

Jennison Associates LLC boosted its position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 262.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 387,483 shares of the company's stock after purchasing an additional...

Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-palvella-therapeutics-stock...

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has received an average rating of "Moderate Buy" from the fifteen ratings firms that are presently covering the stock, Marketbeat reports...

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - What's Next?

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up - Time to Buy...

Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA

Deltec Asset Management LLC decreased its position in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 80.8% in the 4th quarter, according to the company in its most recent filing with the...

Palvella Therapeutics (NASDAQ:PVLA) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen downgraded Palvella Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fifteen research firms that are covering the company, MarketBeat.com...

Lifesci Capital Brokers Decrease Earnings Estimates for PVLA

Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Investment analysts at Lifesci Capital lowered their FY2026 earnings per share (EPS) estimates for Palvella Therapeutics in a note issued to...

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics Inc.

Why Did PVLA Stock Surge 37% Today?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

PVLAPalvella Therapeutics Inc

Fundamentals

Latest PVLA News